The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwNHL 2018 | Immunotherapy for NHL: checkpoint inhibitors, considerations & the future
Immunotherapy is at the forefront of research into novel treatments for lymphoma. Here, John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci, of Barts Cancer Institute, London, UK, Stephen Ansell, MD, PhD, of the Mayo Clinic, Rochester, MI, and Robert Chen, MD, from the Toni Stephenson Lymphoma Center, City of Hope, Duarte, CA, discuss this exciting topic. The experts explore the use, limitations and future of immune checkpoint regulators in NHL. In addition, important differences between the use of immunotherapies in solid vs. hematological malignancies are covered. This video was recorded at the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2018 meeting, held in Nice, France.
